Jaguar Health, Inc. (NASDAQ:JAGX) Q2 2022 Earnings Conference Call August 22, 2022 8:30 AM ET

Company Participants

Lisa Conte - Founder, President, and Chief Executive Officer

Carol Lizak - Chief Financial Officer

Ian Wendt - Chief Commercial Officer

Conference Call Participants

Operator

Before I turn the call over to management, I'd like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of products, the impact of competitive product and pricing, industry trends and product initiatives including products in the development stage, which may not achieve scientific objectives or meet stringent regulatory requirements.

Forward-looking statements are subject to risk and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. These statements are based on currently available information, with management's current assumptions, expectations, and projections about future events.

While management believes its assumptions, expectations, and projections are reasonable in view of currently available information, you are cautioned not to place undue reliance on these forward-looking statements.

The company's the actual results may differ materially from those discussed during this webcast for a variety of reasons, including those described in the forward-looking statements and risk factors sections of the company's Form 10-K for the year 2021, which was filed March 11, 2022 and its other filings with the SEC, which are available on the Investor Relations section of Jaguar's website. Except as required by law, Jaguar undertakes no obligation to update or revise any forward-looking statements contained in this presentation to reflect new information, future events, or otherwise.

Additionally, please note that the company's supplements its condensed consolidated financial statements presented on a GAAP basis by providing gross sales, non-GAAP EBITDA, and non-GAAP recurring EBITDA. Jaguar believes that the disclosure items of these non-GAAP measures provide investors with additional information that reflects the basis upon which company management assesses and operates the business.

These non-GAAP financial measures should not be viewed in isolation or as a substitute for GAAP net sales and GAAP net loss and are not substitute for/or superior to measures [our] [ph] financial performance and the conformity with GAAP. Today's conference is being recorded.

At this time, it is my pleasure to turn the call over to Lisa Conte, Jaguar Health's Founder, President, and Chief Executive Officer. The floor is yours Lisa.

Lisa Conte

Thank you. That’s quite a mouthful to start with. Welcome all, as you just heard, my name is Lisa Conte, and I am the Founder, President, and CEO of Jaguar Health and our wholly-owned subsidiary in the United States Napo Pharmaceuticals. I am also Chairman of the Board of Napo Therapeutics, the corporation we established in Milan, Italy last year to which we granted an exclusive license to crofelemer in Europe, and I'll be speaking about that more later. But I'm going to begin today with the key top line results for the second quarter of 2022.